Biopolymer-Based Adhesives for Biomedical and Industrial Use: Recent Advances, Challenges and Future Directions

Biopolymer adhesives are moving toward frontline use in medicine and manufacturing as the limitations in some petrochemical systems, including cytotoxicity, challenges in wet adhesion for specific families of synthetic resins and formaldehyde emissions associated with amino-formaldehyde materials are becoming increasingly difficult to accept. This review integrates mechanisms, material classes and quantitative performance across biopolymer-based adhesives. We focus on architectures that combine permanent covalent anchoring with reversible, energy-dissipating bonds and on how functional group density, crosslink density, microstructure and additives act as design knobs for wet performance, durability and degradation. Across biomedical applications, chitosan, alginate, gelatin and related hydrogels achieve wet lap-shear strengths on the order of tens of kilopascals, cut liver-bleeding times by roughly half, provide strong antibacterial activity and close diabetic wounds by about 92 percent by day 14. Thermoresponsive alginate–gelatin sealants exceed clinically relevant burst pressures and microneedle patches withstand more than 120 mmHg while sealing arteries in under a minute. In industrial settings, dialdehyde-based starch resins deliver 0.83 to 1.05 MPa dry shear and maintain strength after water immersion while meeting stringent emission classes, and silane-modified nanocellulose in urea–formaldehyde markedly reduces free formaldehyde without sacrificing the internal bond. We conclude by identifying priorities for standardized wet testing, and lifetime matching of strength and degradation that can support large-scale clinical and industrial translation.